linkedin post 2013-12-14 15:47:10

AD has become a dangerous venture for drug companies. Part of the reason for past failures is that the patient pool is heterogeneous. Any drug tested in such a pool will have a diluted statistical power. Aricept may be a good drug in a clean pool. The need to have a homogeneous patient pool will be solved by diagnostics. Secondly, florid AD is probably too late to rescue. The brain is simply too compromised. Going earlier to Mild Cognitive Impairment is intuitively more likely to succeed. FDA has opened that door.

http://lnkd.in/dg77Em5

View in LinkedIn